Vascular-targeting agent

From WikiMD's WELLNESSPEDIA

(Redirected from Vascular disrupting agent)

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1]

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

Clinical trials[edit]

Phase II : ZD6126, CA4P, plinabulin (NPI-2358)[2][3][4]

Phase III : DMXAA (ASA404).

References[edit]

  1. "Vascular Targeting Agents as Cancer Therapeutics".2004;Full text.
  2. NPI-2358(link). clinicaltrials.gov.
  3. Monica M. Mita."Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas".Clin Cancer Res.2010;16(23)
    5892–5899.doi:10.1158/1078-0432.CCR-10-1096.PMID:21138873.
  4. Staff."Clinical Trials Update".Genetic Engineering & Biotechnology News.2009;29(8)
    58.



WikiMD logo

This article is a stub

You can help WikiMD by registering and expanding it with useful details, internal links, formatting, and categories.

Editing is available only to registered and verified users. WikiMD is a comprehensive, free health and wellness encyclopedia.


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.